The National Marrow Donor Program: how it works, accomplishments to date
- PMID: 2701411
The National Marrow Donor Program: how it works, accomplishments to date
Abstract
As the use of bone marrow transplantation increases, the lack of a suitable matched sibling donor for approximately 60% of patients is a growing problem. Recently, marrow transplantation has been done successfully using HLA-matched unrelated donors. In an effort to provide more donors, the National Marrow Donor Program (NMDP) was established. It involves 50 blood banks and 20 marrow transplant centers throughout the United States. More than 20,000 HLA-typed apheresis donors from these blood banks have agreed to be listed in the NMDP registry. A preliminary search for donors has been carried out for 1,116 patients. Donors suitably matched for HLA-A and B antigens were located for 99% of the patients.
Similar articles
-
The National Marrow Donor Program: improving access to hematopoietic stem cell transplantation.Clin Transpl. 1999:121-7. Clin Transpl. 1999. PMID: 11038630
-
Unrelated-donor marrow transplants: the experience of the National Marrow Donor Program.Clin Transpl. 1994:295-301. Clin Transpl. 1994. PMID: 7547550
-
Unrelated-donor marrow transplants: the experience of the National Marrow Donor Program.Clin Transpl. 1995:271-7. Clin Transpl. 1995. PMID: 8794273
-
Marrow transplantation using volunteer unrelated donors in a comparison of mismatched family donor transplants: a Seattle perspective.Bone Marrow Transplant. 1994;14 Suppl 4:S39-41. Bone Marrow Transplant. 1994. PMID: 7728123 Review.
-
HLA and bone marrow transplant donor search strategies.J Assoc Physicians India. 2002 Jul;50:937-45. J Assoc Physicians India. 2002. PMID: 12126352 Review.
Cited by
-
Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.Immunol Res. 2008;41(1):56-78. doi: 10.1007/s12026-007-0043-x. Immunol Res. 2008. PMID: 17989941 Review.
-
The need for uniform and coordinated practices involving centrally manufactured cell therapies.J Transl Med. 2022 Apr 25;20(1):184. doi: 10.1186/s12967-022-03385-9. J Transl Med. 2022. PMID: 35468789 Free PMC article.
-
Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory.Transfusion. 2024 Feb;64(2):357-366. doi: 10.1111/trf.17703. Epub 2024 Jan 3. Transfusion. 2024. PMID: 38173340 Free PMC article.
-
Expanding the reach of commercial cell therapies requires changes at medical centers.J Transl Med. 2024 Feb 19;22(1):181. doi: 10.1186/s12967-024-04966-6. J Transl Med. 2024. PMID: 38374090 Free PMC article.
-
A survey on preoperative autologous blood donation policy in bone marrow stem cell donors in Italy.Blood Transfus. 2023 Jul;21(4):337-344. doi: 10.2450/2022.0134-22. Epub 2022 Dec 5. Blood Transfus. 2023. PMID: 36580031 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical
Research Materials